Gross Margin

Ironwood Pharma forecasts a massive profit jump by lowering its top drug's price, a bold move as it advances its rare disease pipeline for future growth.

RPM International's 52nd straight year of dividend hikes cements its 'Dividend King' status. We look at the strategy behind this rare achievement.

Following the sale of its legacy business, the newly-rebranded Accendra Health launches on the NYSE with a laser focus on the booming home healthcare market.

Innocan Pharma is set to debut on the NYSE American, aiming to boost its innovative CBD drug delivery platform for non-opioid pain relief. What's next?

Aeromexico repeats as the world's most on-time airline, while Qatar Airways earns top honors for operational excellence in Cirium's 2025 rankings.

Insurtech firm PolicyStreet launches its largest promo yet, offering deep discounts and flexible payments to challenge traditional insurers in Malaysia.

Despite falling revenue and supply chain chaos, CanadaBis posts positive cash flow, signaling a disciplined new strategy for survival and sustainability.

With a 79% drop in net loss and a fourth straight growth quarter, supplement maker Vitality Products Inc. bets on new hires to conquer online and retail.

With strong financials and new clinical data, medical device leader Penumbra is set to detail its growth strategy at healthcare's top investor event.

Facing a Nasdaq delisting threat, China-based WF International has 180 days to revive its stock after a dramatic collapse since its April IPO.

Facing market headwinds, tea supplier Oriental Rise makes a bold move to acquire a major producer, aiming to secure its supply chain and boost quality.

Profound Medical raises over $42M to advance its AI-powered, incision-free therapies for cancer and other diseases, signaling strong investor confidence.

Amid economic headwinds, the M&A advisor thrived by securing over 90 deals and promoting key partners, signaling strong momentum for healthcare sales in 2026.

Riding a wave of record revenue and a favorable reimbursement outlook, iRhythm's upcoming JPM presentation is a key test for its 2026 growth strategy.

After eliminating over $10.7M in debt, cannabis operator LEEF Brands leverages strong Q3 growth to fuel major expansion in California and New York.

With soaring revenue and a landmark FDA approval for its Shield cancer test, Guardant Health's upcoming JPM presentation is poised to define its future.

The semiconductor equipment firm will release crucial 2025 and 2026 financial guidance in January, offering a key early test of the industry's momentum.

The Danish firm scraps its 2025 revenue forecast, accepting a larger loss in a bold move to secure more lucrative future deals for its key drug candidates.

Mount Logan Capital offers shareholders a 14% premium in a $15M tender offer, signaling confidence despite mixed financials and a complex market identity.

With Rick Ross and Wiz Khalifa, Gopuff's NYE deals are more than a promotion; they're a play for market dominance in the competitive instant delivery space.